【据Hepatology 2012年2月报道】题:GS-9450治疗NASH患者的Ⅱ期随机双盲安慰剂对照研究(作者Ratziu V等)在NASH中,肝细胞凋亡的程度与疾病的严重度相关。通过选择性caspase抑制剂GS-9450减少肝细胞凋亡具有潜在的改变肝病进程的作用。巴黎第六大学和巴黎Pitié-Salpêtrière医院进行了一项Ⅱ期随机双盲安慰剂对照研究。 Title: A Phase II, Randomized, Double-Blot, Placebo-Controlled Study in Patients with NASH Treated with Hepatology February 2012 (by Ratziu V, et al) In NASH, the extent of hepatocellular apoptosis correlates with the severity of the disease. Reducing hepatocyte apoptosis through the selective caspase inhibitor GS-9450 has the potential to alter the course of liver disease. A Phase II randomized, double-blind, placebo-controlled study was performed at Université Paris VI and the Pitié-Salpêtrière Hospital in Paris.